Drugs / 1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00529113 Background | Sep 2007 → Nov 2009 | malignant pancreatic neoplasm | Biogen | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00529113 ↗ |
| Route | Intravenous | “administered as an intravenous infusion” NCT00529113 ↗ |